Pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast cancer

COM701 as a monotherapy and in combination with nivolumab for various advanced solid tumours

Do immune checkpoint inhibitors work in EGFR mutant lung cancer?

COVID-19: Using oncology drugs and surgery during the coronavirus pandemic

IMPRIME 1: Combination of pembrolizumab and a novel innate immune activator, Imprime PGG, in second-line mTNBC

COVID-19: Management of non-small cell lung cancer patients during the coronavirus pandemic

Managing toxicities associated with immune-checkpoint inhibitors

I-SPY 2: Durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer

IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients with BRAFV600 mutation-positive advanced melanoma

An oncologist's experience of managing breast cancer during the COVID-19 outbreak

COVID-19: The situation in Florida and managing lung cancer patients

The potential of KRAS inhibitors for non-small-cell lung cancer